By Kelly Knaub ( February 6, 2015, 2:54 PM EST) -- Amgen Inc. asked a California federal judge on Friday to grant it a preliminary injunction in its fight with Sandoz Inc. over a biosimilar version of Neupogen, arguing that Sandoz's market entry will be illegal and will irreparably harm Amgen and that an injunction is in the public interest....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.